OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
